Overview
Chart Your Path in the Management of AML: Guidance from MD Anderson Expert Faculty
AML Pathfinder: An Immersive Learning Platform
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This enhanced digital algorithm combines stepwise practical guidance with evidence-based educational context to deliver an immersive learning opportunity for clinicians who strive to provide their patients with Acute Myeloid Leukemia (AML) the best possible care. The ‘choose your path’ environment allows clinicians to select a clinical area of their interest and navigate AML management based on a patient’s disease status (newly diagnosed or relapsed/refractory) and cytogenetic and molecular profiles, with the help of expert guidance. In the process, current practice guidelines and recent therapy approvals and their supporting data are reviewed, which afford clinicians new therapeutic avenues to enhance the health outcomes of their patients with AML.
This is a targeted activity to increase awareness and the application of clinical evidence to develop personalized treatment strategies to optimize the care of patients with AML. Hematology, oncology, are the primary focus. Other healthcare professionals involved in the care or treatment of patients with AML may include pharmacists, oncology nurses, nurse practitioners, and physician assistants.
Over the past 2 years, the Food and Drug Administration (FDA) approved 8 therapies for treatment of AML, representing a dramatic therapeutic advance in this field. While guidelines for AML management are widely available, the treatment paradigm for AML is undergoing a rapid change given the landscape of recent approvals and disease subtype characterizations based on cytogenetic and mutational profiling. Clinicians may not be adequately knowledgeable about clinically relevant biomarkers for AML, and may not be adequately prepared to effectively and safely employ new therapies. Clinicians need education and guidance on individualizing therapy for patients with newly diagnosed and relapsed/refractory AML, while managing treatment-related toxicities. To bridge these gaps, the pathfinder platform is designed to provide an immersive learning experience tailored to the responses of each learner, with practical guidance on incorporating new treatment options integrated with latest clinical data and guidelines.
At the conclusion of this educational activity, the participant should be able to:
• Review and highlight treatment strategies based on the most current clinical practice guidelines, new approvals and approaches for patients with newly diagnosed acute myeloid leukemia (AML). (Knowledge, Competence, Performance, Patient Outcomes)
• Discuss strategies for implementing recent drug approvals and review evidence-based regimens for specific patients with relapsed or refractory AML, including management of toxicities. (Knowledge, Competence, Performance, Patient Outcomes)
• Evaluate the prognostic implications of molecular and cytogenic features of AML and discuss applying this information into new treatment strategies in mutation-harboring patients (Knowledge, Competence, Performance, Patient Outcomes)
• Review and highlight treatment strategies based on the most current clinical practice guidelines, new approvals and approaches for patients with newly diagnosed acute myeloid leukemia (AML). (Knowledge, Competence, Performance, Patient Outcomes)
• Discuss strategies for implementing recent drug approvals and review evidence-based regimens for specific patients with relapsed or refractory AML, including management of toxicities. (Knowledge, Competence, Performance, Patient Outcomes)
• Evaluate the prognostic implications of molecular and cytogenic features of AML and discuss applying this information into new treatment strategies in mutation-harboring patients (Knowledge, Competence, Performance, Patient Outcomes)
Supported by educational grants from AbbVie Inc. and Astellas Pharma Inc.
Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX